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INTRODUCTION
Endotracheal  intubation  is  an  integral  part  of  administration  of  anaesthesia  during 
surgical procedures. Suxamethonium, a depolarizing muscle relaxant with its rapid onset and 
short duration of action is still the relaxant of choice to facilitate tracheal intubation. In addition 
to fasciculations, Suxamethonium has got many side effects such as bradycardia and other 
dysrhythmias, rise in serum potassium, post operative myalgia, rise in intraocular, intragastric 
and  intracranial  pressure,  prolonged  recovery  in  patients  with  pseudo-cholinesterase 
deficiency and triggering  of  malignant  hyperthermia.  Because most  of  the side effects  of 
Suxamethonium reflect its depolarizing mechanism of action, search for ideal neuromuscular 
blocking agent focused on non-depolarizing type of relaxants which has rapid onset time and 
offers good to excellent intubating conditions, as rapidly as Suxamethonium and which lacks 
the above mentioned adverse effects.
 Pancuronium  (0.15  –  0.2  mg/kg)  will  provide  intubating  conditions  in  90  seconds. 
Tachycardia and prolonged muscle relaxation become a problem.
 Vecuronium (0.2 mg/kg) provides adequate intubating conditions only after 90 seconds.
 Atracurium (0.5 mg/kg) will allow safe intubation in 3 minutes. A larger bolus (1.5 mg/kg) 
will  allow intubation in 60 – 90 seconds, but may cause hypotension, tachycardia, and 
histamine release.
 Cis-atracurium (0.1 – 0.15 mg/kg) is not recommended for rapid sequence endotracheal 
intubation. A dose of 0.4 mg/kg (8 x ED 95) will allow intubation in 90 seconds without 
histamine release, but the duration of action may exceed 60 minutes.
 Rapacuronium  (1.5  mg/kg)  has  a  more  rapid  onset  of  action  than  Rocuronium  or 
Mivacurium with good to excellent tracheal intubating conditions within 1 minute in 85% of 
the adult patients, and duration of action of approximately 10 – 20 minutes. Its clinical 
efficacy rivals that of Succinylcholine, but with slightly slower onset and longer duration. It 
would clearly be the best choice of non-depolarizing muscle relaxant for rapid sequence 
intubation because of its rapid onset of action, minimal cardiovascular side effects even at 
large doses, and short duration of action. However, it is no longer available, having been 
withdrawn by the manufacturer in March 2001.
 An alternative is to pre-treat the patient with a small dose of the non-depolarizing muscle 
relaxant  several  minutes before induction, which may shorten the onset of  action and 
lessen the dose required of subsequently administered relaxant. This has been referred to 
as  a  ‘priming’  dose.  Its  use  is  controversial  in  that  it  may  lead  to  diplopia,  muscle 
weakness, respiratory distress, and aspiration while offering no definite advantage over 
the use of larger initial doses of non-depolarizing muscle relaxants.
 Rocuronium (0.6 – 1.2 mg/kg), has a rapid onset and an intermediate course of action, 
providing excellent intubating conditions at 60 – 70 seconds. Several studies have shown 
that the onset of action of Rocuronium is significantly faster when compared to equipotent 
doses of other non-depolarizing agents discussed above. Hence, Rocuronium was chosen 
for rapid sequence intubation in the present study.
AIMS OF THE STUDY
1. To  compare  the  intubating  conditions  of  Rocuronium  with  Suxamethonium  at  60 
seconds, in emergency surgeries following rapid sequence intubation.
2. To compare the hemodynamic response to intubation 
RAPID SEQUENCE INTUBATION
Securing and maintaining a patent airway reserves the highest priority when caring for 
critically ill or injured patients. When airway intervention is required it should be performed in 
an expedient and organized fashion by an experienced individual with the goal of providing a 
definitive airway safely, minimizing any possible complications. Rapid sequence intubation or 
RSI has just this goal in mind and to be performed successfully, takes experience, a thorough 
understanding of its indications, contraindications and limitations, and a working knowledge of 
the physiology and pharmacology of agents used. 
Rapid  sequence  intubation  (RSI)  is  defined  as  the  rapid  (nearly  simultaneous) 
administration  of  both  a  neuro-muscular  blocking  agent  and  a  potent  sedative  agent  to 
facilitate  intubation  while  decreasing  the  risks  of  aspiration,  combativeness  and  potential 
damage to the patient. Rapid sequence intubation is developed to secure the airway of a 
critically  ill  or  injured  patient  rapidly  and  safely.  It  applies  to  virtually  all  attempts  for 
endotracheal intubation in the emergency departments except for arrest situations 42, 43, 44. RSI 
is particularly preferred for emergency use because of the simultaneous onset of sedation, 
paralysis and minimizing the risk of aspiration 26. After being launched in the late seventies, 
the procedure has been dynamically changing in time with introduction of many newer and 
advantageous agents. 5, 7, 35
Rapid sequence intubation protocol is still in development in order to minimize the 
risk of aspiration of gastric contents in case of “full stomach” while preventing secondary 
brain injury via rendering unconsciousness and paralysis and to achieve higher rates of 
successful  endotracheal  intubation.  Muscle  relaxants  are  given  as  part  of  a  rapid-
sequence  induction  to  facilitate  tracheal  intubation.  Among  all  the  muscle  relaxants 
available, Succinylcholine is the only one with a rapid (approximately equal to 1 min) onset 
and a fast recovery. Therefore it is still the most frequently used muscle relaxant for rapid-
sequence induction despite its well-known side effects.  The short duration of action of 
Succinylcholine is, however, no substitute for aggressive airway management in the case 
of an unexpectedly difficult intubation in order to prevent life-threatening hypoxia. 
A preoperative assessment  of  the airway is  mandatory in  any patient  and may 
indicate the need for using intubation techniques without a muscle relaxant. Laryngoscopy 
and intubation are performed after administering rapid and short-acting sedative, hypnotic 
and amnestic agents in conjunction with neuromuscular blocking agents  18. Short-acting 
agents like Succinylcholine are generally preferred for fear of protracted intubation failure 
32, 41. For decades, Succinylcholine used to be the sole agent demonstrated to consistently 
provide  paralysis  in  less  than  one  minute.  3,  40,  51 It  is  still  the  sole  depolarizing 
neuromuscular blocking agent used in the procedure. It is particularly useful in the critically 
ill or injured with a full stomach for which an RSI technique is needed 14. Patients intubated 
in emergency conditions generally have full  stomach and rapid  intubation is  critical  to 
prevent  aspiration  of  gastric  contents.  Succinylcholine  provides  a  means  for  rapid 
intubation in these high-risk patients. Rocuronium is diverse from other non-depolarizing 
agents being the first one with a short onset time devoid of adverse effects. The object of 
this is study is comparing the use of Succinyl choline and Rocuronium in   rapid sequence 
intubation protocol in adults.
The induction agent  is  immediately followed by administering the paralytic  agent,  and 
ventilation is not assisted once the patient is  paralyzed.  Pre-oxygenation is done prior  to 
administering any agents and cricoid pressure is applied until airway establishment has been 
confirmed.
The sequence is as follows: 6 ‘P’s
1. P  repare  equipment  (intubation  kit,  ambu  bag,  suction,  RSI  meds,  combi-tube, 
cricothyrotomy kit, CO2 detection devices.)
2. P  reoxygenate patient with 100% oxygen for atleast 2 minutes. If trauma or spinal injury 
is suspected, 2nd care giver will hold manual stabilization.
3. P  retreatment/ Premedication : LOAD 
Lignocaine – 1.5mg/kg
Opioid – fentanyl 1-2 μ/ kg
Atropine – 10-20 μ/ kg
Defasciculation – 10% of paralyzing dose
4. P  aralysis  with  induction. Administer  Etomidate (0.2-0.6mg/kg){alternative midazolam 
(2-5mg)}. Administer Succinylcholine (1mg/kg). 
5. P  rotection  of  the  airway.  Apply  cricoid  pressure  (Sellick’s  maneuver)  46 by  a  3rd 
caregiver. 
6. P  lacement with proof. Intubate the patient and verify tube placement.
7. Release cricoid pressure and secure tube placement. Reassess tube placement often 
especially when moving patient.
8. Document procedure, time, and results on the Anesthesia case record.
MODIFICATIONS OF RSI:
1. MODIFIED  RSI
 Gentle ventilation allowable
2. ACCELERATED RSI
 Shortening preoxygenation-30secs-by 8 vital capacity breaths
 shortening pretreatment - 2mts from 3mts
3. IMMEDIATE RSI
 Eliminate pretreatment
 Pre-oxygenate with 8 vital capacity breaths
a) Indications:
Any patient at risk of aspiration, which includes the following
• patients with full stomach (any emergent case or trauma patient)
• pregnant patients
• patients with known reflux, hiatal hernia, or delayed gastric emptying
b) Contraindications: 
• Spontaneous breathing with adequate ventilation and oxygenation. 
• Operator’s  concern  that  both  intubation  and  mask  ventilation  may  not  be 
successful due to: major laryngeal trauma; upper airway obstruction; distorted 
facial or airway anatomy. 
• Operator unfamiliarity with the medications used. 
The true contraindication to rapid sequence intubation is any patient whom you may not be 
able to intubate or perform a cricothyroidotomy. Contrary to belief, the presence or suspicion 
of cervical spine injury is not a contraindication to rapid sequence intubation.
Disadvantages:
1. Prevents the hyoid bone from moving forward with the tongue during laryngoscopy.
2. It  may  cause  lingual  nerve  damage  by  stretching  the  nerve  as  it  crosses  the 
hyoglossus, and lead to hyper aesthesia of the tongue.
3. Misplaced pressure can drive the thyroid up under the wings of the hyoid cartilage, 
reducing the visualization available for insertion of the tracheal tube.
ANATOMY AND PHYSIOLOGY OF 
NEURO MUSCULAR JUNCTION
HISTORY:
1555 - Tracheal insufflation in animals was described by Andreas Vesalius of Padua.
1878 – William MacEwen of Glasgow passed a tube from mouth into the trachea, using 
his fingers as a guide in the conscious patient.
1901 – Franz Kuhn of Kassel extended the technique by using a flexible metal tube 
introduced on a curved guide through the mouth, palpating the epiglottis with the fingers of his 
left hand.
1907  –  Barthelemy and  Dufour  of  Nancy,  blew chloroform vapour  and  air  from a 
Vernon Harcourt inhaler and a rubber guided into the trachea by touch  – the first use of 
insufflation endotracheal anesthesia.
1928 – Magill published his results of blind nasal intubation with a wide-bore rubber 
tube. The first blind nasal intubation was performed by Stanley Rowbotham.
Before the days of muscle relaxants, blind nasal intubation was popular. The use of 
muscle relaxants to facilitate intubation was pioneered by Bourne.
1850 - Claude Bernard showed that curare acts by paralyzing the myoneural junction. This 
led to his discovery of the concept of motor end-plate.
1934 – Sir Henry Dale described the physiological actions of acetyl choline and its association 
with neuromuscular transmission. 
1942 – Harold R. Griffith and Enid Johnson used curare to give relaxation during surgery on 
23rd January in Montreal, Canada, a famous day in the history of anesthesia.
1949 – Daniel Bovet et al introduced Suxamethonium.
1951 – Suxamethonium was first used in anesthesia by Otto Von Dardel in Stockholm and 
Otto Meyerhofer in Vienna.
1956 – W.D.M. Paton made the distinction between the depolarizing and non-depolarizing 
relaxants.
ANATOMY & PHYSIOLOGY:
Neuromuscular Junction (NMJ) is a synapse at which an electrical impulse traveling 
down  a  nerve  is  converted  into  muscle  action  potential  and  contraction  by  chemical 
transmitters. A motor neuron, along with all the muscle fibres supplied by it forms a motor 
unit, which follows all or none law of contraction.
PARTS OF NEUROMUSCULAR JUNCTION:
To understand the physiological events occurring during neuromuscular transmission it is 
essential to understand the anatomy of NMJ, which can be divided into,
1) Presynaptic nerve terminal
2) Synaptic cleft
3) Post Synaptic membrane-Acetylcholine receptors
4) Contractile apparatus
Fig. 2
PRESYNAPTIC NERVE TERMINAL:
Presynaptic nerve terminal contains all the apparatus necessary for the synthesis of 
acetylcholine, which exists in two forms:
1. 20% in the soluble (storage) form in the presynaptic axoplasm and 
2. 80% in vesicles (releasable), which can be further, divided into a readily available pool and 
a reserve pool.
 The vesicles are 40-50nm in diameter each containing 1000-10000 molecules of Ach. The 
walls of the vesicles contain synapsins that help in anchoring the vesicle to the cytoskeletal 
framework of the axoplasm.
At the membrane facing the synaptic cleft, there is an electron dense patch, the active 
zone,  around  which  the  readily  available  pools  of  Ach  vesicles  are  arranged.  Electron 
microscopy  shows  small  pores  between  the  vesicles  at  the  active  zone.  These  are  the 
calcium channels. The terminal also contains sodium and potassium channels.
The nerve endings on fast muscles are longer and more complicated than those on 
slow muscles. The reason for this is unclear. These differences in the nerve endings on the 
muscle surfaces may play a role in the differences in the response to muscle relaxants of fast 
and slow muscles.
SYNAPTIC CLEFT:
It is 20nm wide space between the nerve terminal and the muscle end plate. The nerve 
and muscles are held in tight alignment by protein filaments, which span the cleft between 
nerve and end plate. The muscle surface is heavily corrugated with deep invaginations of the 
junctional  cleft,  the  primary clefts  and the  secondary clefts,  between the  folds  in  muscle 
membrane. The shoulders of the folds are densely populated with acetylcholine receptors 
about 5 million of them in each junction. These receptors are spares in the depths between 
the folds. Instead these deep areas contain sodium channels. These sodium channels have 
two component gates, voltage and time dependent gates.
POST SYNAPTIC MEMBRANE – ACETYL CHOLINE RECEPTORS:
The Ach receptors at the NMJ are nicotinic and can be divided into pre synaptic and 
postsynaptic. The latter are further divided into junctional and extrajunctional.
The Ach receptor is a pentameric transmembrane spanning protein (class IV). The 5 
protein  subunits  are  arranged  in  the  form  of  a  rosette  with  a  central  ion  channel.  The 
molecular weight of the receptor is 250000-270000. The mature junctional receptor contains 2 
α and 1 β, δ, ε sub-units. The immature extra junctional receptor contains 2 α  and 1 β, δ, γ 
sub-units, which proliferate in abnormal conditions. The extra cellular surface of the alpha 
subunits contains high affinity Ach binding sites. Margin of safety: where in up to 70-80% of 
the receptors can be occupied before surgical relaxation develops.
CONTRACTILE APPARATUS:
The contractile apparatus of the muscle is formed by the myofilament comprising the 
thin actin filaments and thick myosin filaments, along with tropomyosin, troponin I, T and C. 
Tropomyosin is attached to the myosin binding site of actin.
The myofilaments combine to form myofibrils.   The muscle plasma membrane, the 
sarcolemma invaginates to form T-tubules which lie in close association with sarcoplasmic 
reticulum which is a collection of sacs and tubules acting as a reservoir for calcium.
MECHANISM OF ACETYL CHOLINE RELEASE:
An  action  potential  traveling  down  the  nerve  causes  the  sodium  channels  in  the 
presynaptic nerve terminal to open, leading to sodium influx. The change in voltage produced 
by such an influx activates the calcium channels, which open up leading to calcium entry. 
Calcium  mediated  activation  of  calcium-calmodulin  dependent  protein  kinases  lead  to 
phosphorylation of synapsins in the vesicle wall, causing the vesicles to break away from the 
cytoskeletal  framework.  The vesicles then attach to the active zones with release of Ach 
molecules.  Each  nerve  impulse  causes  the  release  of  around  100-400  quanta  of  Ach. 
Activation of around 20-25% receptors is essential for impulse transmission.
MECHANISM OF NEUROMUSCULAR TRANSMISSION
BINDING OF ACETYL CHOLINE TO RECEPTOR:
The Ach molecule released into the synaptic cleft binds to the alpha subunit. Binding of 
Ach to both the alpha subunits activates the receptor, leading to configurational changes in 
the receptor structure and opening up of ion channels. This leads to depolarization of the 
muscle end plate which when of a sufficient magnitude causes a wave of depolarization to 
spread across the muscle sarcolemma by means of activation of the voltage dependent gates 
of the sodium channels in the peri junctional zones. This depolarization wave moving down 
the T tubule causes release of calcium from sarcoplasmic reticulum. Calcium so released 
binds to troponin C causing tropomyosin to move and expose the myosin binding sites of 
actin leading to the formation of cross linkage of actin and myosin heads. They slide over 
each other leading to shortening of the myofilaments and muscle contraction.
DISSOCIATION OF ACETYL CHOLINE FROM RECEPTOR:
The Ach molecule remains attached to its receptor for a very short period of less than 1 
millisecond, after which it  dissociates from the receptor and is hydrolyzed by the enzyme 
acetyl cholinesterase. It hydrolyses Ach into acetate and choline, the choline being taken up 
by the presynaptic nerve terminal and used for further Ach synthesis.
MECHANISM OF NON-DEPOLARIZING BLOCKADE:
Non-depolarizing muscle relaxants are drugs having an affinity for the alpha subunits 
of the acetylcholine receptors mainly at the post-junctional nicotinic receptors and also at the 
pre-junctional  sites  of  nerve  ending.  Binding  of  these relaxants  to  the α  subunits  of  Ach 
receptors can not open the ion channel and it also prevents further binding of Ach molecule. 
So an action potential is not developed and there is no contraction of muscle fiber.  This 
competitive blockade of Ach receptor is termed as non-depolarizing blockade. Atleast 75% of 
receptors must be occupied before neuromuscular transmission is impaired and if more than 
90% of the receptors are occupied, transmission fails.
CHARACTERISTIC FEATURES:
1) Slow onset to maximal effect and slow recovery compared to Succinylcholine.
2) The central muscles like the diaphragm, larynx, masseter, orbicularis oculi tend to be 
affected earlier and recover from the block sooner than those of the peripheral muscles 
(adductor pollicis) probably as a result of preferential perfusion.
3) Presence of fade and post tetatnic potentiation.
4) Despite flaccid paralysis, the muscles are still able to respond to direct stimulation.
5) Anticholinesterase drugs reverse the muscle block pharmacologically.
6) Low potency drugs like rocuronium and Rapacuronium have rapid onset of action while 
potent  relaxants  like  Doxacurium and pancuronium have relatively  slower  onset  of 
action and a longer duration of action.
MECHANISM OF DEPOLARIZING NEUROMUSCULAR BLOCKADE
Depolarizing  agents  like  Suxamethonium,  have  a  biphasic  action  causing  an  initial 
depolarization of the endplate due to their acetylcholine like actions, followed by relaxation. 
The  sodium  channel  is  a  cylindrical  transmembrane  protein  that  has  3  functional 
conformational states, with 2 functional gates, an upper voltage dependent gate and a lower 
time dependent gate. Sodium ion passes only when both these gates are open. 
I. At rest: Upper gate – closed
Lower gate - open
II. Depolarization:   Upper gate – open
Lower gate - open
III. Shortly after :      Upper gate – open
Lower gate - closes
IV. Repolarization:   Upper gate – closed
Lower gate – open
Continuous end-plate depolarization causes muscle relaxation because opening of the 
lower gate in the peri-junctional sodium channels is time limited. After the initial excitation and 
opening, these sodium channels close and cannot re-open until end-plate repolarizes. The 
end-plate cannot repolarize as long as the depolarizing muscle relaxant continues to bind to 
Ach  receptors,  because  the  upper  gate  can  close  only  when  the  receptor  sites  are  not 
occupied. Consequently the lower gate can open only when the upper gate closes, being able 
to return to the resting or repolarized state. This is phase I block.
After a period of time, prolonged end-plate depolarization can cause ionic and conformational 
changes in the Ach receptor that result in a phase II block.
Thus, in a depolarizing blockade, the muscle membrane is divided into 3 zones
1. the end plate – which is depolarized by Succinylcholine
2. the  peri  junctional  membrane  –  in  which  the  sodium  channels  are  frozen  in  an 
inactivated state
3. rest  of  the  muscle  membrane  –  in  which  the  sodium channels  are  in  the  resting 
excitable state
This phenomenon is also called accommodation, where the synapse is unexcitable via the 
nerve  but  direct  electrical  stimulation  of  the  muscle  will  cause  muscle  contraction. 
Accommodation does not occur in the extra-ocular muscles.
PHARMACOLOGY
ROCURONIUM (org 9426)
STRUCTURE:
Rocuronium  is  a  monoquarternary  aminosteroid,  chemically,  2-morpholino,  3-
desacetyl, 16-N-allyl pyrrolidino derivative of vecuronium, differing from it at 3 positions on 
steroid nucleus.
 Introduced into clinical practice in 1994.
MOLECULAR STRUCTURE:
Fig. 5
PRESENTATION:
As  a  clear  colorless  solution  containing  10  mg/ml  of  Rocuronium  bromide.  It  is 
available in 5ml & 10ml Vials.
ROUTES OF ADMINISTRATION:
Intravenous/ Intramuscular.
Doses (IV):-
ED95 : 0.3 mg / kg
Intubation at 60 – 90 sec : 0.6 – 0.9 mg / kg
Relaxation (N2O / O2) : 03 – 04 mg / kg
Relaxation (Vapor) : 0.2 – 0.3 mg / kg
Maintenance : 0.1 – 0.15 mg / kg
Infusion : 8 – 12 μ / kg / min.
Doses (IM): into the deltoid
Infants : 1mg/kg
Children : 1.8 mg/kg
Rocuronium is not recommended for use in neonates.
Mechanism of action/Effect:
     
 Rocuronium is a non-depolarizing neuromuscular blocking agent with a rapid onset of 
action, depending on dose, and with an intermediate duration of action. Rocuronium produces 
neuromuscular  blockade  by  competing  with  acetylcholine  for  cholinergic  receptors  at  the 
motor end plate.  It is 7-8 times less potent than vecuronium. Thus a greater number of drug 
molecules are able to reach junctional receptors within a fewer circulation times, enabling 
faster development of neuromuscular blockade. Low potency leads to a weaker binding to 
receptors and prevents buffered diffusion, a process that occurs with potent drugs, which 
causes repetitive binding and unbinding to receptors. Diffusion of less potent drugs away from 
the receptors very likely occurs much more readily, thereby helping to limit the duration of 
blocking effect. This is most likely reason why the duration of action of Rocuronium remains 
intermediate. 
Onset of action: 
ED 90 – it is the dose required to produce 90% depression of the twitch response of the 
thumb  to  stimulation  of  the  ulnar  nerve.
With  doses of  0.6  mg Rocuronium per  kg  of  body weight  administered  over  5  seconds; 
effective  intubating  conditions  are  achieved  within  60  to  90  seconds. Onset  of  action  of 
Rocuronium may be delayed in patients with conditions, such as cardiovascular disease and 
advanced age, associated with slowed circulation. The onset of action is faster in infants and 
children than in adults.
When IM route is chosen in infants & children, tracheal intubation can be performed in 
2.5 – 3 mins with a duration of 2 hours.
Time to peak effect: 
The time to peak effect is dependent on dosage, the age of the patient, and the anesthetic 
administered concurrently. The median times to maximum block are given below. 
Adults 18 to 64 years of age under opioid–nitrous oxide–oxygen anesthesia:
0.45 mg/kg:  3 (range, 1.3–8.2) minutes. 
0.6 mg/kg: 1.8 (range, 0.6–13) minutes. 
0.9 mg/kg:  1.4 (range, 0.8–6.2) minutes. 
1.2 mg/kg: 1 (range, 0.6–4.7) minute 
Duration of action:
The CLINICAL DURATION (the duration until spontaneous recovery to 25% of control  
twitch height) of action with 0.6 mg/kg is 30 – 40 mins.
The TOTAL DURATION (time until spontaneous recovery to 90% of control twitch height) is 
50 mins. 
The  mean  time  of  spontaneous  recovery  of  twitch  response  from  25  –  75% 
(RECOVERY INDEX) after a bolus dose of 0.6 mg/kg is 14 mins.
As the dose is increased, the recovery slows. The duration of action is also limited by avid 
liver uptake and elimination into the bile, due to an increase in the lipophilic nature of the 
molecule  with  respect  to  vecuronium.
Duration of clinical effect (the time until spontaneous return of the twitch response to 25% of  
control value as determined using a peripheral nerve stimulator) is dependent on dosage. 
Median time to spontaneous recovery from 25 to 75% of the control value is 13 minutes in 
adults.
During  rapid  sequence  induction  of  anaesthesia  under  propofol  or  fentanyl/thiopental 
anaesthesia, adequate intubation conditions are achieved within 60 secs. In 93% and 96% of 
the patients respectively, following a dose of 1mg/kg rocuronium bromide. Of these 70% are 
rated excellent.
Following a dose of 0.6 mg/kg, adequate intubation conditions are achieved within 60 secs. in 
81% and 75% of the patients during a rapid sequence induction technique with propofol or 
fentanyl/Thiopentone  respectively.
The clinical duration is shorter in children than in adults.
With  doses  higher  than  1  mg/kg,  the  intubating  conditions  will  not  improve  appreciably. 
However the duration of action will be prolonged.
Adults 18 to 64 years of age— 
0.45 mg/kg—22 (12–31) minutes.
0.6 mg/kg—31 (15–85) minutes. 
0.9 mg/kg—58 (27–111) minutes 
1.2 mg/kg—67 (38–160) minutes 
Maintenance dose:
0.075-0.15 mg/kg given when the twitch height has recovered to 25% of control twitch 
height, or when 2 or 3 responses to TOF is present. No cumulation of effect with repetitive 
maintenance dosing at the recommended level has been observed.
Continuous infusion:
 A loading dose of 0.6 mg/kg is administered, and the infusion is started at 0.3 – 0.6 
mg/kg/hr,  when the neuromuscular function starts to recover.  The infusion rate should be 
adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 or 2 
responses to TOF.
 Distribution: 
Rocuronium has a biphasic distribution. The rapid distribution half-life is 1 to 2 minutes 
and the  slower  distribution  half-life  is  14 to  18 minutes.  Approximately 80% of  the  initial 
Rocuronium  dose  is  redistributed.  As  administration  of  Rocuronium  continues,  tissue 
compartments fill. Within 4 to 8 hours, less Rocuronium is redistributed away from the site of 
action,  and  the  dosage  requirement  to  maintain  neuromuscular  blockade  via  continuous 
infusion  falls  to  about  20%  of  the  initial  infusion  rate.  
Vd – 203  (193 – 214) ml/kg
Cl – 3.7 l (3.5 – 3.9) ml/kg/min; t1/2 – 73 (66 – 80) mins.
Protein binding:
 Low (30%) 
Biotransformation:
    Deacetylated in the liver to 17-desacetyl-rocuronium (ORG 9943) and 16-N-desallyl-
rocuronium (ORG 20860), these are usually not detectable in plasma and therefore are not 
expected to contribute significantly to the pharmacodynamic effects of Rocuronium.
 Elimination:
Rocuronium is primarily eliminated by the liver, with a small fraction (10%) eliminated 
by the kidneys. It is taken up into the liver by a carrier mediated active transport system. 
Rocuronium is excreted in urine and bile. Excretion in urine approaches 40% within 12 – 24 
hrs. 
Hepatic disease:
In hepatic disease (most commonly cirrhosis), the volume of distribution of Rocuronium 
is increased, and its clearance is decreased. The duration of action is prolonged and its onset 
may  be  prolonged.  Consequently  dosing  in  patients  with  hepatic  disease  should  be 
conservative and guided by careful monitoring of neuromuscular function.
Adult and geriatric patients with normal hepatic function:
1.4 ± 0.04 hours during opioid–nitrous oxide–oxygen anesthesia and 2.4 ± 0.08 hours during 
Isoflurane anesthesia. 
Adult and geriatric patients with hepatic function impairment:
 4.3 ± 2.6 hours during Isoflurane anesthesia
Renal failure:
In patients with renal failure, the plasma clearance of rocuronium may be decreased, 
and its volume of distribution is increased. The duration of action of single and repeated dose 
is  not  significantly  affected.  In  the  elderly,  the  clearance  is  decreased  and  volume  of 
distribution  is  increased,  with  consequent  prolongation  in  duration  of  action.  
Cardiovascular effects:
The cardiovascular effects of muscle relaxants may be produced by
1. muscarinic receptor block
2. ganglionic block
3. increased nor-adrenaline release
4. blockade of nor-adrenaline uptake
5. histamine liberation
Initial  animal  studies  with  Rocuronium  suggested  the  occurrence  of  muscarinic 
receptor  and  ganglion  blocking  effects  only  with  doses that  are  much higher  than those 
required for neuromuscular block.36
Further studies in dogs confirmed that cardiovascular effects were minimal with doses of up to 
3xED95, although the heart rate tended to increase with doses greater than 5xED95. 9
Routine  measurements  of  heart  rate  and  arterial  pressure  during  neuromuscular 
studies showed that rocuronium had minimal effects on these variables with doses of 2-3 
ED95 11, 51
The autonomic margin of safety for vagal block (3.0-5.0) is about 10 times less than 
that  of  vecuronium.  In  equipotent  doses (2xED  95), the  administration  of  rocuronium was 
associated with a small increase in heart rate of 7% (not statistically significant). However, 
there was increase in cardiac index of about 11% (statistically significant). There was little 
change in mean arterial pressure.
Rocuronium causes increases in heart rate of over 30% of baseline in some patients. 
While the etiology of the tachycardia is believed to be multifactorial, pain on injection or vagal 
blockade may contribute to tachycardia. Rocuronium is more likely than vecuronium but less 
likely  than  pancuronium  to  cause  tachycardia.  
Histamine liberation:
Rocuronium may cause histamine release. In a study of histamine release, 1 of 88 
(1.1%) patients receiving rocuronium had clinically significant concentrations of histamine. In 
pre-marketing clinical trials, Rocuronium administration was accompanied by clinical signs of 
histamine release (e.g., flushing, rash, or bronchospasm) in 9 of 1137 (0.8%) patients. No 
clinical evidence of histamine release was observed in the 45 patients enrolled in one study 
designed to provoke histamine release by the rapid injection of Rocuronium. No significant 
histamine release with doses of Rocuronium up to 3xED95.
Cumulation:
Lack of cumulation has also been demonstrated by the absence of significant change 
in the dosage of Rocuronium required to maintain stable relaxation with infusions lasting for 
over 2h.
Reversibility and post –operative curarization:
When adequate spontaneous recovery (an average of >T1 of 25%) has occurred, the 
neuromuscular block induced with Rocuronium can be easily antagonized by edrophonium or 
neostigmine.
Anaphylactic/anaphylactoid reactions:
No such anaphylactic/anaphylactoid responses have so far  been reported following 
administration of Rocuronium.
IOP & ICP:
Rocuronium appears to be safe, in terms of minimal changes in IOP, for use in rapid 
sequence induction  for  anesthesia  in  perforated  eye  injuries,  particularly  if  rocuronium is 
administered before the induction agent, as in the case of vecuronium. Neither vecuronium 
nor rocuronium have any significant effect on ICP.
Other actions/effects:
Rocuronium shows no significant interaction with commonly used antibiotics as given 
for prophylaxis immediately prior to surgery. 
The duration of  action of  Rocuronium may be prolonged in patients  with marked hepatic 
disease. The clearance of Rocuronium may be reduced in patients with renal failure. However 
there was no significant increase in the duration of action of Rocuronium in these patients nor 
was  there  any  significant  difference  in  the  elimination  half-life.
Side/Adverse Effects:
Pain on injection – especially when the patient has not completely lost consciousness 
and when particularly propofol is used as an inducing agent, in rapid sequence induction. 
hiccups, nausea, vomiting, hypertension, hypotension, arrhythmia, bronchospasm, pruritus, 
rhonchi, skin rash, swelling at injection site, tachycardia, wheezing. 
Parenteral Dosage Forms: 
For rapid sequence intubation— 
Intravenous, 0.6–1.2 mg per kg of body weight.
This dose results in blockade sufficient for intubation in one (range, 0.4–6) minute, allows 
intubation to be completed within two minutes, and achieves maximum blockade within three 
minutes. 
A lower dose of 0.45 mg per kg of body weight may be used with a small prolongation 
of  time to  blockade sufficient  for  intubation  (1.3  minutes)  and of  time to  achievement  of 
maximum blockade  (within  4  minutes).  With  a  dose  of  0.45  mg per  kg  of  body weight, 
intubation can still be accomplished in most patients within two minutes.
Doses of 0.9 and 1.2 mg per kg of body weight have been administered during surgery 
under opioid–nitrous oxide–oxygen anesthesia without adverse cardiovascular effects. 
The use of a priming dose (i.e., administration of ten percent of the dose of Rocuronium, 
followed three minutes later by the remaining ninety percent of the intubating dose) 
significantly shortened the onset time in one study. However, the peripheral intravenous 
injection of priming doses into patients who are conscious can be expected to be associated 
with burning pain on injection. Patients may experience sensations of weakness and difficulty 
in breathing after receiving a priming dose.
Maintenance: 
Intravenous—  
Doses of 0.1, 0.15, and 0.2 mg per kg of body weight given when twitch response returns to 
twenty-five percent of the control value provide a median of twelve (range, 2–31), seventeen 
(range, 6–50), and twenty-four (range, 7–69) minutes, respectively, of clinical relaxation under 
opioid–nitrous oxide–oxygen anesthesia. Additional maintenance doses should be guided by 
recovery of neuromuscular function following the initial dose and should not be administered 
until  recovery  of  neuromuscular  function  is  evident.  
Intravenous infusion — 
0.01 to 0.012 mg per kg of body weight per minute after evidence of recovery from the 
intubating dose. Additional doses may be needed until steady state has been achieved. The 
rate of the maintenance infusion must be individualized for each patient and should be guided 
by the patient's twitch response to peripheral stimulation. In clinical trials, satisfactory 
blockade was obtained with maintenance infusion rates of 0.004 to 0.016 mg per kg of body 
weight per minute.
SUCCINYL CHOLINE
History:
1906 – Reid hunt described its pharmacological actions
1949 – Bovet et al described its neuromuscular blocking actions
1951 – Thesleff first used the drug in man at Stockholm
The first report on the administration of SCh for performing ETI in multiple cases in the ED 
was published by Thompson et al in 1982. 
Chemistry:
Succinyl choline is a synthetic muscle relaxant, a quaternary amine ester, consisting of 
two molecules of acetylcholine joined together through their acetyl groups.
Molecular Structure:
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Presentation:
As a solution, it is available in 10ml vials containing 50mg/ml and in vials containing 
100mg powder form.
Storage: 40C. Spontaneous hydrolysis occurs in warm/alkaline conditions.
Routes of administration:
Intravenous/ Intramuscular
Dose
ED95 - 0.51 – 0.63 mg/kg
Intubation dose - Adults:  1-1.5 mg/kg IV bolus
Children:  2-2.5 mg/kg
Onset of action - 30 to 60 sec.
Duration of action - 4 to 10 min.
Mechanism of action:
It is the only depolarizing muscle relaxant in use today. It has a rapid onset (30 – 60 
secs) and short duration (<10 mins) of action. Rapidity is due to its low lipid solubility and the 
relative overdose that is usually administered. The drug binds to presynaptic, postsynaptic 
and extrajunctional receptors, where it exhibits an Ach like activity. Succinyl choline attaches 
to each of the alpha subunits of the nicotinic cholinergic receptor and mimics the action of 
Acetyl Choline thus depolarizing the post junctional membrane. Here, the hydrolysis is slow 
resulting in sustained depolarization (opening) of the receptor ion channels.
Neuromuscular blockade develops because a depolarized post junctional membrane 
cannot  respond  to  subsequent  release  of  Acetyl  Choline  (Depolarizing  Blockade).  It  is 
otherwise called as 
Phase I Blockade, which is characterized by 
• Absence of fade with TOF or tetanic stimulation.
• Absence of post titanic facilitation
• Increased blockade with anticholinesterase drug such as Neostigmine and 
Edrophonium
 The presynaptic receptors are involved in the production of fasciculations.
Phase II Blockade : (non-depolarizing/dual)
• Single large dose of succinyl choline (> 2mg /kg IV)
• Repeated small doses of succinyl choline 
• Prolonged continuous infusion 
may result in post junctional membranes that do not respond normally to Acetyl choline even 
when the post junctional membranes have become repolarized. Mechanism for this blockade 
is unknown. Phase II block is a complex and ever-changing phenomenon. Desensitization is 
one  of  the  many  factors  that  contribute  to  the  process.  Phase  II  blockade  has  non-
depolarizing characteristics such as
• fade with TOF or titanic stimulation
• post tetanic facilitation
• antagonism of blockade with anticholinesterase agents
The development has 4 phases
Phase A – depolarizing block which may last 30 – 50 mins.
Phase B – non-depolarizing block develops quite quickly
Phase C – a plateau 30 min. period of no change
Phase D – a wearing-off phase up to 2 hour long
Reversal of phase II blockade by cholinesterase inhibitors is best not attempted.
Metabolism:
Succinylcholine  is  rapidly  hydrolyzed  by  plasma  cholinesterase  to  choline  and  succinyl 
monocholine.
Succinyl choline
Plasma cholinesterase (rapid)
Succinyl monocholine + choline
Plasma cholinesterase (slow)
Succinic acid + choline
Dibucaine number and pseudocholinesterase activity:
Dibucaine,  a local  anaesthetic,  inhibits  the normal  pseudocholinesterase activity by 
about 80% and the homozygous atypical enzyme by about 20%. The heterozygous enzyme is 
characterized  by  an  intermediate  40  –  60%  inhibition.  The  percentage  of  inhibition  of 
cholinesterase  by  10-5 molar  solution  of  dibucaine  is  termed  the  dibucaine  number.  The 
percentage of  inhibition of  cholinesterase by 5 x 10-5 molar  sodium fluoride is termed as 
Fluoride  number.  Dibucaine  number  indicates  the  genetic  make  up  of  an  individual  with 
respect to pseudocholinesterase. It does not measure the concentration of the enzyme in the 
plasma nor does it indicate the efficiency of the enzyme in hydrolyzing the substrate such as 
succinyl choline. The activity of the enzyme refers to the number of substrate molecules in 
mmols  hydrolyzed  per  unit  of  time.  Pseudocholinesterase  activity  is  certainly  markedly 
influenced by the genotype, but is also dependent on the concentration of the enzyme in the 
plasma.  Of  the  population  94% are  normal  Eu Eu  genotypes  (homozygous  atypical)  with 
normal enzyme activity and a dibucaine number of 75 – 85.
Three abnormal genes exist:
1. Ea (atypical) homozygotes comprise 0.03% of the population 
2. Ef (fluoride resistant) homozygotes comprise 0.0003% of the population
3. Es (silent) homozygotes comprise 0.001% of the population.
 Normal serum cholinesterase level is about 80 u/ml
type of pseudo
cholinesterase
genotype frequency dibucaine 
number
response
to suxa
Homozygous 
typical
Eu Eu Normal 70 – 80 Normal
Heterozygous Eu Ea 1/ 480 50 – 60 Slightly 
prolonged
Homozygous 
atypical
Ea Ea 1/3200 20 – 30 Markedly 
prolonged
Abnormalities of Suxamethonium metabolism:
1. Abnormal plasma cholinesterase (inherited): 
i. Atypical  cholinesterase  –  Mendelian  recessive  Ea Ea  homozygotes  (1/3000 
population) have 1 – 2 hours apnoea, during which phase 2 block develops (DN 16 
– 25). Heterozygotes EuEa (1/25 population) have little or no disturbance (DN 50 – 
65), with apnoea up to 10 mins.
ii. Fluoride resistant – homozygotes have 1 hour apnoea, with phase II block (DN 16 – 
25). Heterozygotes have 10 min apnoea (DN 50 – 65).
iii. Silent gene 
2. Plasma cholinesterase deficiency 
Factors lowering pseudocholinesterase concentration are
i. liver disease
ii. pregnancy
iii. burns
iv. drugs – OCPs, MAO inhibitors, echothiophate, cytotoxic drugs, anticholinesterases, 
tetrahydroaminacrine, metoclopramide, hexafluorenium, banbuterol, Esmolol.
v. neoplastic disease
Adverse Effects:
1. Prolonged apnoea 39, 54: 
As discussed above, patients with abnormal pseudocholinesterase or deficient enzyme 
will experience markedly prolonged paralysis (range: 20 mins – 8 hrs.)
2. Cardiovascular effects  4, 6, 8, 17, 22, 25, 29, 37, 45, 49, 50:
Bradycardia:  It  is  the  most  frequently  encountered  change  in  rate,  especially  in 
children due to high sympathetic tone. It is usually seen after the administration of relatively 
large single  dose injections.  The higher  incidence of  bradycardia  after  a  second dose of 
succinyl choline suggests that the hydrolysis products of succinyl choline may sensitize the 
heart to a subsequent dose.
 Succinylcholine stimulates all cholinergic autonomic receptors – nicotinic receptors on 
both sympathetic and parasympathetic ganglia, and muscarinic receptors in the sinus node of 
the heart. In low doses, both negative inotropic and chronotropic responses may occur and in 
large doses, these effects may become positive. One prominent clinical manifestation of this 
generalized autonomic stimulation is the development of cardiac arrhythmias, such as nodal 
bradycardia  and  ventricular  ectopics,  ventricular  fibrillation.  Succinylcholine  lowers  the 
ventricular threshold to catecholamine induced arrhythmias. A high vagal background may 
predispose to asystole when a single dose of succinyl choline is administered. 
3. Fasciculations:
Appear within a few seconds of succinyl  choline administration and are most often 
evident in young muscular adults. They are uncommon in children and intensity is less in the 
elderly.  Muscle  fasciculations  can  increase  serum potassium level  by 0.5-1.0  meq/L  and 
produce  arrhythmias  The  mechanism  is  most  likely  a  depolarization  of  nerve  terminals 
through succinyl choline’s action at the presynaptic receptors. This produces anti-dromic firing 
in the nerve, with the propagation of the action potential to all branches supplying a motor 
unit. The extension of fasciculations in the body is dependent on the arterial blood distribution. 
Muscles close to the aorta and receiving the drug first are early affected. 
4. Muscle pains:
There is an increased incidence of post-operative myalgia, 24 – 48 hrs after succinyl 
choline, more frequently following minor  surgery,  especially in  women and in ambulatory. 
Pregnancy  and  extremes  of  age  seem  to  be  protected.  Pain  is  secondary  to  damage 
produced in muscle by the unsynchronized contractions of adjacent muscle fibres just before 
the onset of paralysis. The finding of myoglobinemia and increased serum Creatine kinase 
following Sch administration substantiates this. The efficacy of non-depolarizing pre-treatment 
is controversial.
5. Hyperkalemia 20, 51
Potassium is released from muscles following suxamethonium injection, causing a rise 
of serum potassium of 0.2 – 0.4 mmols/L. A life threatening elevation of potassium is possible 
in patients with 
a) Massive trauma, closed head injury
b) Muscular dystrophy, neuropathies, denervation, stroke
c) Third degree Burns
d) UMN/ LMN Lesions
e) Tetanus
f) Spinal cord injuries
g) Congenital cerebral palsy
h) Wasting secondary to chronic arterial insufficiency
i) Prolonged total body immobilization
j) Severe intra-abdominal injury
In  denervation,  the  extra-junctional  receptors  allow  succinyl  choline  to  effect  widespread 
depolarization and extensive potassium release. 
6. Malignant Hyperpyrexia 24, 53:
Suxamethonium  is  a  potent  triggering  agent  in  patients  susceptible  to  malignant 
hyperthermia, together with potent inhalation agents.
7. Masseter muscle spasm 21:
Paradoxical contraction of jaw muscle following Succinyl choline may be a premonitory 
sign of malignant hyperpyrexia.
8. Increased Intra Gastric Pressure 19, 42: 
Increases to >20 mmHg due to severe muscle fasciculations. However, it causes a 
greater rise in lower esophageal sphincter tone, and hence it does not appear to increase the 
risk of aspiration unless the LES is incompetent, such as in pregnancy, hiatus hernia and 
obesity.
 9. Increased Intra Ocular Pressure 38: 
Suxamethonium 1 mg/kg raises the pressure by 7mm Hg partly as a result of tonic 
contraction of the extra-ocular muscles. The increase in IOP is manifested within 1 minute 
after  injection,  peaks  at  2-4  mins,  and  subsides  by  6  mins.  The  phenomenon  of 
accommodation  does  not  occur  in  extra  ocular  muscles.  The  extra  ocular  muscles  also 
contain a special type of receptor that do not become desensitized in the continued presence 
of acetyl choline or other agonists.
10. Increased intracranial pressure 33:
A mean increase of 5 mm Hg over the baseline is observed. This may have serious 
consequences with intra-cranial compliance is limited.
REVIEW OF LITERATURE
1) Ajeet Singh, Bhatia Pradeep Kumar, Tulsiani Kishan Lal 2 (2004)
In a prospective randomized double blind study, tracheal intubating conditions, using 0.6 
mg/kg Rocuronium (Group A) and 1.5 mg/kg Suxamethonium (Group B) were compared 
in 40 patients. The time to achieve maximum blockade and the clinical duration of action 
were also compared by twitch stimulation using biometer accelograph. All patients were 
premedicated with inj. pentazocine, inj. diazepam and inj. atropine and induced with inj. 
thiopentone. Intubating conditions were assessed and graded at 60 seconds after injection 
of  relaxant.  While  the  onset  time and duration  of  action  were  found to  be  more  with 
rocuronium but the results showed no significant difference in the intubating conditions 
achieved in both the groups.
2) Andrews JI., et al (1999) Compared Rocuronium and Succinylcholine for rapid sequence 
induction of anaesthesia along with propofol and anesthesia was induced using propofol 
2.5mg/kg  followed  immediately  by  either  rocuronium  0.6mg/kg  or  1mg/kg  or 
succinylcholine 1mg/kg. Intubating conditions were assessed at one minute and intubation 
was performed. They concluded rocuronium 1mg/kg given along with propofol in a rapid 
sequence induction of anaesthesia is clinically equivalent to Succinylcholine 1mg/kg.
3) In the study by Awarez-Gomez et al, 3 (1994) the intubating conditions of standard doses 
of vecuronium and Rocuronium were compared at 60 secs or 90 secs. At 60 sec after 
administration of Rocuronium, excellent conditions were present in all patients. 
4) K.Barclay., et al (1997)  assessed whether low doses of Rocuronium improved conditions 
for  tracheal  intubation  during  induction  of  anaesthesia  with  Propofol  2.5mg/kg  and 
alfentanil 10ug/kg. They have studied three groups. One group received saline, second 
group Rocuronium 0.1 mg/kg and the third group received 0.3mg/kg Rocuronium and they 
assessed the intubating conditions as judged by jaw opening and laryngoscopy, position 
of the vocal cords and degree of straining after tracheal intubation. They concluded that 
injection of Rocuronium 0.3mg/kg with Propofol and alfentanil provided a high proportion 
of optimal intubating conditions.
5) Cooper et al  11   found the onset time for Rocuronium 0.6 mgkg-1 as 90 sec by 0.1 Hz 
stimulation and 58 sec using TOF stimulation. 
6) Cooper  R,  Mirakhur  RK,  Clarke 34 (1992)  compared  intubating  conditions  after 
administration  of  Rocuronium  and  Suxamethonium  and  concluded  that  Rocuronium 
0.6mg/kg  produces  clinically  acceptable  intubating  conditions  at  60  seconds  after 
induction with Thiopentone 5mg/kg.
7) J.D. Crul  12  & Colleagues (1995) observed clinically acceptable intubating conditions at 
45 seconds with Rocuronium 0.6mg/kg
8) De Mey J.C.,  et  al13 (1994) evaluated  onset  and intubating conditions  of  Rocuronium 
bromide 0.5, 0.75 or 0.9mg/kg in adult patients anaesthetized with Propofol 2mg/kg and 
alfentanil 0.5 to 1  µg/kg. They concluded that a dose of Rocuronium equal to or larger 
than 0.6 mg/kg provides acceptable intubations at 60 seconds after administration.
9) Dubois et al, 15 Huizinga et al.(1995): In these studies no difference was observed in the 
frequency distribution of clinically acceptable intubating conditions at 60 secs and 90 secs 
after the administration of Suxamethonium or Rocuronium.
10)Kirkegaard – Nielsen H., et al.(1999) 23 studied rapid tracheal intubation with Rocuronium 
using a probability based approach. 80 adult patients anaesthetized with Fentanyl 2μg/kg 
and  Propofol  2mg/kg  randomly  received  Rocuronium  0.0,  0.4,  0.8,  or  1.2  mg/kg 
(n=20/dose).   Laryngoscopy  was  initiated  at  40  seconds  aiming  for  intubation  at  60 
seconds. Doses giving 90 and 95% probability of successful intubation were calculated 
and found to be 0.83 and 1.04mg/kg respectively. Estimated times until first tactile train of 
four  response after  ED50 and ED95 doses were 32 and 46 minutes respectively.  They 
concluded that after induction with Fentanyl and Propofol, Rocuronium 1.04 mg/kg gives 
95% probability of successful intubation at 60 seconds.
11)Lam AM., et al (2000)  27   compared the onset and offset time and intubating condition 
after 1min obtained with Rocuronium bromide 0.6mg/kg and Succinylcholine 1mg/kg after 
induction with Propofol and Fentanyl. They concluded that Rocuronium 0.6mg/kg, when 
used with  Propofol  and Fentanyl  for  induction provides intubating conditions similar  to 
Succinylcholine 1mg/kg at 1 minute.
12)Land and Stovner 28 (1962) were probably the first to introduce a rating scale as a tool for 
the assessment of intubating conditions in which the three main criteria: Jaw relaxation, 
vocal cords (position and motility) and reaction to intubation were rated by descriptive 
scores such as excellent, satisfactory or fair but this allows a large room for subjective 
interpretation  of  data.  These  three  main  criteria 66  remained  the  basis  of  numerous 
subsequent modification of their rating scale by others. One of the most frequently used 
modifications,  still  in  use  today,  was introduced by  Krieg et  al  26 in  1980 in  which  a 
numeric  value  is  assigned  to  signify  quality  of  intubating  conditions.  Cooper’s 
modification of this rating scale was used in the present study.
13)Magorian et al 30  (1993) compared the duration of action of Rocuronium in doses of 0.6 
mgkg-1, 0.9 mgkg-1 and 1.2. mgkg-1 with that of Suxamethonium in the dose of 1 mgkg-1. 
They were found to be 2220 sec, 3180 secs, 4380 sec and 540 secs respectively. In our 
study duration of action of Rocuronium 0.6 mgmkg-1 and Suxamethonium 1.5 mgmkg-1 
are 1704 secs and 318 sec respectively.
14)Mazurek  A  J  ;  Hann  S.  compared  Rocuronium  versus  Succinylcholine  for  Rapid 
Sequence induction  and concluded larger doses of Rocuronium  may be an alternative to 
Suxamethonium.
15)In a trial by Mc Court et al 32,(1998) tracheal intubating conditions during rapid induction 
of anaesthesia using 0.6 mgkg-1 Rocuronium or 1 mgkg-1 Suxamethonium, were studied 
and conditions were scored at 60 secs. Intubating conditions were found to be equally 
acceptable in both groups.
16)Mirakhur R.K. et al (1994) 34  compared onset and intubating conditions of Rocuronium 
bromide  0.6mg/kg  and  Suxamethonium  1mg/kg  in  adult  patients  anaesthetized  with 
Thiopentone,  N2O in  oxygen  and  small  doses  of  Fentanyl.  Intubating  conditions  after 
Rocuronium 0.6mg/kg were found to be clinically acceptable.(good or excellent)in 95% of 
patients at 60 seconds and in all patients at 90 seconds and in all patients at both times 
after  Suxamethonium.  There  was  no  significant  difference  in  acceptable  intubating 
conditions between Suxamethonium and Rocuronium.
17) Peter M.C. Wright., et al (1994) 57  studied the onset  and duration of Rocuronium and 
Succinylcholine at the adductor pollicis and laryngeal adductor muscles in anaesthetized 
adults.  They found that the onset of effect  with Succinylcholine was significantly more 
rapid at the laryngeal adductors (34+/-12 sec) than at the adductor pollicis (56+/-15 sec.) 
Onset  times  were  similar  at  the  two  muscle  groups  with  Rocuronium 0.8  and  1.2mg 
(96+/-29 and 74+/- 36 sec. with 0.8 mg/kg and 54+/-30 and 65+/- sec with 1.2mg/kg at the 
laryngeal adductors and the adductor pollicis, respectively.)  Rocuronium 0.4mg/kg had a 
more rapid effect at the laryngeal adductors than the adductor pollicis (92+/-29 sec. and 
155+/- sec. respectively). They concluded that the laryngeal adductors are more resistant 
to the action of Rocuronium than is the adductor pollicis. Onset of effect of Rocuronium in 
doses greater than 0.8mg/kg is similar to that of Succinylcholine at the adductor pollicis 
but  is  significantly  delayed  compared  with  that  of  Succinylcholine  at  the  laryngeal 
adductors.
18)Previs TH, Zahn P., et al (1994) Studied the ED95 dose of Rocuronium bromide and the 
tracheal intubating conditions and time course of actions. They concluded the ED95 dose of 
Rocuronium bromide was 0.3mg/kg and duration of action was 20 minutes.
19) Puhringer et al 41 (1992) and Dubois et al 15 (1995) found the onset times as 72 sec and 
48  sec  and  130  secs  and  74  secs  respectively  for  Rocuronium  600  μ/kg  and 
Suxamethonium 1mg/kg respectively. 
20) Sparr 48 and Crul  et  al,12 (1996)  investigated  Rocuronium’s  potential  in  emergency 
intubating conditions using it strictly according to the scenario for rapid sequence induction 
in unpremedicated but still elective cases. In those studies, the frequency distribution of 
‘excellent’, ‘good’ or clinically acceptable intubating conditions, 60 secs after 600 mcg/kg 
or  900  mcg/kg  Rocuronium  were  compared  with  those  observed  after  1  mgkg-1 
Suxamethonium. The results indicate that intubating conditions were more favorable at 60 
sec after administration of Rocuronium in the dose of 900 mgmkg-1 compared to dose of 
600 mgmkg-1 in unpremedicated patients. In premedicated patients, who received 600 
mgmkg-1  Rocuronium after  induction  with  I.V.  anaesthetic,  intubating  conditions  were 
comparable with those obtained with a dose of 900 mgmkg-1 Rocuronium.
21)Watanabe K, Chen K., et al (1991) described the pre and postsynaptic effects of org 
9426 (Rocuronium) during the onset and recovery from neuromuscular blockade. They 
found that  the  relaxant  to  have moderate  potency with  rapid  onset  time,  intermediate 
duration of action and rapid recovery.
22) Wierda et al 56 (1995) compared the onset time of Rocuronium 250 μg/kg and found it to 
be 220 sec and 190 secs respectively.
MATERIALS AND METHODS
Study design:
This study was a randomized prospective comparative study.
Study setting and population:
         After obtaining institutional ethical committee clearance, the study was carried out on 40 
patients  in  the  emergency  OT,  Department  of  Anesthesiology,  Madras  Medical  College, 
Chennai, from January to June 2005.
         The patients were randomly selected from either sex, between 18 to 60 years of age, 
and  weighing  between  50-70  kgs.  Emergency  cases  posted  under  G.A.  and  assessed 
between  ASA  status  I  –  III,  without  significant  disturbance  in  hemodynamic  status  or 
metabolic/electrolyte/ acid-base disturbance were chosen. These cases included 
1. neurosurgical emergencies for craniotomy & evacuation such as
    extra-dural / sub-dural haematoma and depressed fracture of the skull.
2. blunt injury abdomen for laparotomy
3. hollow viscus perforation
4. acute appendicitis for appendicectomy
5. vascular/tendon injuries of the upper limb
6. compound fracture both bones of the fore-arm for external fixator application
INCLUSION CRITERIA:-
∗ Adults between 18 – 60 years
∗ ASA Physical status I , II & III
∗ Emergency surgeries posted under G.A.
∗ Closed head injuries with GCS > 13
EXCLUSION CRITERIA:-
∗ Children
∗ Pregnancy
∗ Obesity
∗ Known / suspected difficult Intubation
∗ H/o any neuromuscular disorder
∗ Renal / Hepatic disorder
∗ Head injuries with GCS < 13
∗ Hypovolemia/ Shock
∗ Severe metabolic/electrolyte/ acid-base disturbances
∗ Known allergy to drugs.
∗ Surgical procedures of very short duration.
∗ Patients  receiving  any  medication  known  to  interact  with  Neuromuscular  blocking 
agent.
PRE OPERATIVE EVALUATION:-
In all the patients, Age, I.P.No, Body Weight, Baseline vital parameters were recorded. 
History regarding previous anaesthesia, surgery, any significant medical illness, medications 
and allergy were recorded. The fasting time was taken as the time interval between the last 
meal/drink and the time of trauma. Complete physical examination and Airway assessment 
was done. 
Following laboratory investigations were done:
 Hemoglobin %
 Blood : sugar, urea, S. Creatinine
 S. Electrolytes : Na+, K+
 Chest X-Ray 
 ECG in all leads
STUDY METHOD:
Informed consent  was obtained from all  the patients  and they were divided into  2 
groups, group I (n=20) patients receiving Rocuronium bromide (0.6 mg/kg) & group II (n=20) 
patients receiving Suxamethonium (1.5 mg/kg).  To ascertain the ease of intubation, every 
patient  was  examined  for  Mallampati  classification  31 (Young  and  Samson  modification). 
Aspiration prophylaxis with inj. Metoclopramide 10 mg and inj.Ranitidine 50 mg I.V. was given 
to  all  the  patients  half  to  one  hour  prior  induction.  Patients  were  premedicated  with  inj. 
Glycopyrrolate (0.2 mg) and inj. Pentazocine 0.5 mg/kg, I.V. 5 min before induction. 
 In  the  operation  theatre  the  vital  parameters  were  recorded,  venous  access 
established,  and  infusion  of  crystalloid  solution  was  started.  Chest  leads  for  continuous 
cardiac and respiratory monitoring were attached, prior to induction and monitoring started. 
Oxygen saturation was measured by pulse oximeter using a finger probe.
The patients were pre-oxygenated with 100% O2 for 3 minutes and induced with a fixed 
dose of inj. Thiopentone sodium 250 mg I.V. Cricoid pressure was given when Thiopentone 
was administered and released following successful tracheal intubation and inflation of the 
cuff. Where the patient had a Ryle’s tube inserted prior to induction, Sellick’s maneuver was 
carried with Ryle’s tube in-situ.. 
In-group I, inj. Rocuronium bromide was given in a dose of 0.6 mgkg-1 (2 x ED95) and 
the patients in-group II  received Suxamethonium 1.5 mgkg-1. 60 seconds after injection of 
muscle relaxant, the patients were
intubated orally; Simultaneously, intubating conditions were noted and scored according to a 
modification of the method described by 
Mirakhur R.K., Cooper A.R. and Clarke R.S.J (Table 1 & 2)
TABLE –1
SCORING OF INTUBATING CONDITIONS
SCORE JAW 
RELAXATION
VOCAL 
CORDS
RESPONSE TO INTUBATION
0 Poor(impossible) Closed Severe coughing or bucking
1 Minimal(difficult) Closed Mild coughing
2 Moderate(fair) Moving Slight diaphragmatic movement
3 Good(easy) Open None
TABLE –2
GRADING OF INTUBATING CONDITIONS
Intubating Conditions
Score
Excellent 8-9
Good 6-7
Poor 3-5
Bad 0-2
 After  inflating  the  cuff  of  endotracheal  tube,  it  was  connected  to  circle  absorber  and 
controlled ventilation was instituted.
The following hemodynamic parameters 
o Heart rate
o Mean arterial pressure
were recorded continually at
-3 mins. – pre induction values at the onset of  pre-oxygenation
-60 s – administration of muscle relaxant
 0 secs. – intubation
 1 m, 3m & 5m – after intubation.
 Patients were maintained with O2 + N2O, Vecuronium/Atracurium and at the end of 
surgery; muscle paralysis was reversed with inj. neostigmine and inj. Glycopyrrolate. At the 
end of study, the data collected were analyzed statistically. 
OBSERVATION AND RESULTS
The study was conducted on 40 patients randomly allotted into 2 groups as given 
below:-
TABLE – 3
DRUG DOSAGE AND SCHEDULE
Grou
p
Drug and Dose Sample Size
I Rocuronium 0.6 mg/kg 20
II Suxamethonium 1.5 mg/kg 20
 No intubation difficulty was encountered during the study.
 No airway adjuncts were used 
 None of the patients desaturated during the performance of RSI.
 The application of cricoid pressure did not worsen the view during laryngoscopy and 
intubation.
 Few patients  had  Ryle’s  tube  inserted  prior  to  induction,  which  was  not  removed 
subsequently, and Sellick’s maneuver carried out with the Ryle’s tube in-situ.
 All intubations were successful in both the groups during the first attempt.
 No significant adverse effect other than tachycardia & hypertension were noted.
DEMOGRAPHIC PROFILE
I. AGE
TABLE –4
Group n Mean Std. 
Deviation
Student’s 
t-test
Rocuronium 20 29.60 8.982
Suxamethonium 20 31.25 7.656
t=0.63
P=0.54
P > 0.05: Not significant
Statistical  Analysis  using  Student’s  t-test  showed  no  significant  difference  between  the 
distributions of age among the study groups.
AGE DISTRIBUTION
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II. SEX DISTRIBUTION
TABLE – 5
 Group Total
Rocuronium Suxamethonium  
Sex
 
Male 14 12 26
Female 6 8 14
Total 20 20 40
χ2=0.44   P=0.51
14 6 12 8
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SEX DISTRIBUTION
Male Female
Statistical  Analysis  using  Chi-square  test  showed  no  significant  difference  between  the 
distributions of sex among the study groups.
III. TRACHEAL INTUBATING CONDITIONS
The scores for Jaw Relaxation, vocal cord position and response to intubation and the 
total scores were compared between 2 groups.
TABLE - 6
 JAW 
RELAXATION
group Total
Rocuronium Suxamethonium  
Score 3 20 20 40
Total 20 20 40
χ2=0.00   P=1.00
20 20
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JAW RELAXATION
Statistical analysis by Chi-square test showed that there was no difference with respect to jaw 
relaxation among the study groups. A mean score of 3, which corresponded to easy opening 
of the jaw, was observed in all the patients in both the study groups.
TABLE - 7
 VOCAL CORDS group Total
Rocuronium Suxamethonium  
score
 
2 3 0 3
3 17 20 37
Total 20 20 40
χ2=3.24   P=0.07
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Rocuronium Suxamethonium
VOCAL CORDS
Moving Open
Statistical analysis by Chi-square test showed that the condition of the vocal cords during 
intubation with Suxamethonium was not  significantly different  from that  of  Rocuronium. A 
mean score of 2.85 was observed in the Rocuronium group. A mean of 3.0 was observed in 
Suxamethonium group.
TABLE – 8
 Response to 
intubation
group Total
Rocuronium Suxamethonium  
score
 
2 20 0 20
3 0 20 20
Total 20 20 40
χ2=40   P=0.001
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Rocuronium Suxamethonium
RESPONSE TO INTUBATION
Slight diaphragmatic movement None
Statistical analysis by Chi-square test showed that the response to intubation was higher in 
the  Rocuronium  group  and  was  statistically  significant  (P  =  0.001),  from  that  of  the 
Suxamethonium group. Rocuronium showed a mean score of 2 ± 0.0 (slight diaphragmatic 
movement), and Suxamethonium showed a mean score of 3 ± 0.0 (no response).
TABLE – 9
 Total score group Total
Rocuronium Suxamethonium  
score
 
 
7 3 0 3
8 17 0 17
9 0 20 20
Total 20 20 40
χ2=40   P=0.001
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Rocuronium Suxamethonium
TOTAL INTUBATION SCORE
Good Excellent
Statistical  analysis  by  Chi-square  test  showed  that  the  total  intubation  score  with 
Suxamethonium was higher than Rocuronium and was statistically significant (P = 0.001). 
The overall intubating conditions were better with Suxamethonium with a mean total score of 
9. The mean total score in Rocuronium group was 7.85. 
IV. HAEMODYNAMIC PROFILE
MAP
TABLE – 10
MAP Group n Mean Std. 
Deviation
Student’s
t -test
Baseline
 
Rocuronium 20 96.20 14.285
Suxamethonium 20 93.20 10.521
t=0.76
P=0.45
Induction
 
Rocuronium 20 85.25 13.459
Suxamethonium 20 84.95 6.909
t=0.09
P=0.93
Intubation
 
Rocuronium 20 106.65 14.805
Suxamethonium 20 102.65 7.693
t=1.07
P=0.29
1m
 
Rocuronium 20 105.55 14.099
Suxamethonium 20 101.55 7.302
t=1.13
P=0.27
3m
 
Rocuronium 20 104.10 13.626
Suxamethonium 20 99.90 7.144
t=1.22
P=0.23
5m
 
Rocuronium 20 101.90 13.006
Suxamethonium 20 96.75 7.268
t=1.54
P=0.13
10m
 
Rocuronium 20 99.75 12.920
Suxamethonium 20 95.10 8.717
t=1.33
P=0.19
                              TABLE – 11
MAP
 
Group
Rocuronium Suxamethonium
Mean SD Mean SD
Baseline 96.20 14.29 93.20 10.52
Induction 85.25 13.46 84.95 6.91
Intubation 106.65 14.80 102.65 7.69
1m 105.55 14.10 101.55 7.30
3m 104.10 13.63 99.90 7.14
5m 101.90 13.01 96.75 7.27
10m 99.75 12.92 95.10 8.72
TABLE – 12
 
MAP F Sig.
Within group 194.49 .001
Between group 1.09 .301
HEART RATE
TABLE – 13
 Heart 
rate
group n Mean Std. 
Deviation
Student 
t-test
Baseline
 
Rocuronium 20 87.70 12.127
Suxamethonium 20 82.15 10.323
t=1.56
P=0.13
Induction
 
Rocuronium 20 97.10 10.983
Suxamethonium 20 92.00 12.230
t=1.39
P=0.17
Intubation
 
Rocuronium 20 103.65 26.908
Suxamethonium 20 103.55 13.040
t=0.02
P=0.99
1m
 
Rocuronium 20 107.75 13.958
Suxamethonium 20 101.25 13.074
t=1.52
P=0.14
3m
 
Rocuronium 20 101.45 12.804
Suxamethonium 20 97.10 12.876
t=1.07
P=0.29
5m
 
Rocuronium 20 94.35 12.106
Suxamethonium 20 92.95 11.673
t=0.37
P=0.71
10m
 
Rocuronium 20 91.55 10.909
Suxamethonium 20 87.65 10.520
t=1.15
P=0.26
TABLE – 14
 HEART 
RATE
Group
Rocuronium Suxamethonium
 Mean SD Mean SD
Baseline 87.70 12.13 82.15 10.32
Induction 97.10 10.98 92.00 12.23
Intubation 103.65 26.91 103.55 13.04
1m 107.75 13.96 101.25 13.07
3m 101.45 12.80 97.10 12.88
5m 94.35 12.11 92.95 11.67
10m 91.55 10.91 87.65 10.52
TABLE – 15
 Heart rate F Sig.
Within group 35.82 .001
Between group 1.07 .31
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Statistical analyses between groups on MAP and HR in different time were obtained 
using repeated measures of Analysis of Variance.
The  mean  rise  in  MAP and HR was  higher  within  the  groups (P  =  0.001)  during 
intubation, and was statistically significant. 
The rise in MAP & HR between the groups (P = 0.3) showed no statistical significance. 
V. ADVERSE EFFECTS
TABLE – 16
adverse
effect
group
Rocuronium Suxamethonium
Total
 
HT, Tachycardia 2 0 2
Pain 1 0 1
Nil 17 20 37
Total 20 20 40
χ2=3.24   P=0.19
The  adverse  effects  looked  for  were  evidences  of  histamine  release  like  flushing, 
wheal, bronchospasm, hypotension and pain on injection.
No sign of histamine release was noted in any of the patients, in this study. Two of the 
patients in Rocuronium group had hypertension and tachycardia, and 1 patient experienced 
pain during injection. No significant adverse effects were observed in Suxamethonium group. 
Statistical analysis with Chi-square test showed no significant difference in the adverse 
effects between both the groups (P = 0.19).
 Demographic information like age and sex were given in frequencies with percentage.
 Difference between groups on age was analyzed using the Student’s t-test.
 Difference between groups on sex was analyzed using the Chi-square test.
 MAP, HR, Intubation score were given as mean and SD. 
 Statistical analysis between groups on MAP and HR in different time was obtained using 
repeated measures of Analysis of Variance.
DISCUSSION
Traditionally Suxamethonium has been the neuromuscular blocking drug of choice for 
rapid sequence induction and minimizing the chances of regurgitation and aspiration. Since 
its introduction in 1949, Succinylcholine has become the drug of choice to produce paralysis 
in rapid sequence intubation. The use of Suxamethonium can however be associated with 
many side effects like hyperkalemia, bradycardia, cardiac arrest, raised ICP and IOP. Hence, 
a non-depolarizing neuromuscular blocker with a rapid onset of action, preferably of a shorter 
duration is desirable. 
Initial  studies in animals showed that Rocuronium, being a low potency compound, 
was associated with a rapid onset of effect when compared with other compounds such as 
Pancuronium and Vecuronium. 7, 35 This has since been demonstrated in many clinical studies 
that the onset of action of Rocuronium is significantly faster when compared to equipotent 
doses of Atracurium and vecuronium, although slightly slower than that of Suxamethonium. 
That’s why Rocuronium was selected for the purpose of rapid sequence induction, in the 
present study.
The extra anesthetic depth needed, coupled with these laryngeal movements are two 
drawbacks that cannot make the low dose Rocuronium [0.3 mgkg-1 (1xED90)] as a desirable 
technique  for  rapid  sequence  intubation.  Use  of  higher  dose  of  Rocuronium  to  improve 
intubating conditions during rapid sequence intubation and to cut short the onset time below 
60 seconds has been advocated by various workers 1, 12, 13, 51 but doses larger then 0.6 mgkg-1 
would be associated with  a  long duration of  action which may be inappropriate  in  many 
situations.
In most studies, an appropriate timing of tracheal intubation has been determined by 3 
ways.
1. Clinical judgment
2. Neuromuscular monitoring either by twitch suppression (maximum blockade) or TOF ratio
3. Predetermined time after the administration of
neuromuscular blocking agent e.g. 60 secs, 90 secs,
120 secs etc.
The technique using judgment alone is relatively insensitive. Onset time differs with 
different nerve stimulation rates used.
The development of neuromuscular block was not monitored, as it has been clearly 
shown in the studies of  Peter M.C. Wright et al  57 and De Mey et al  13, that there is poor 
correlation between onset time measured at the adductor pollicis and the quality of intubating 
conditions.  So,  for  more  than 40 years,  authors  have abandoned  instrumental  means to 
evaluate laryngoscopy and intubating conditions and are using scales that assess clinical 
criteria only to assess the quality of tracheal intubation. The scale used in the study was used 
originally  by  Cooper  et  al  11.  in  their  study  and  is  recommended  for  studies  with 
neuromuscular blockers 70.
Land and Stovner 28 were probably the first to introduce a  rating scale as a tool for the 
assessment of intubating conditions in which the three main criteria:  Jaw relaxation, vocal 
cords (position and motility) and  reaction to intubation were rated by descriptive scores 
such as excellent, satisfactory or fair but this allows a large room for subjective interpretation 
of data. These three main criteria 66 remained the basis of numerous subsequent modification 
of their rating scale by others. One of the most frequently used modifications, still  in use 
today, was introduced by Krieg et al 26 in 1980 in which a numeric value is assigned to signify 
quality of intubating conditions.  Cooper’s modification of this rating scale was used in the 
present study.
In the  present study, intubation was attempted at 60 secs after the injection of muscle 
relaxant for rapid sequence induction as proposed by Mc Court et al 32, Cooper et al 11, De 
Mey  et al 13, Sparr 48 and Crul et al 12. 
The patients were pre-medicated with 0.5 mg/kg Pentazocine and 0.2 mg Glycopyrrolate 
and Rocuronium (0.6 mg/kg) / Suxamethonium (1.5 mg/kg) given immediately after receiving 
the I.V. anaesthetic, as done in the study by Dr. Ajeet Singh et al  2 
The  condition  of  the  vocal  cords during  intubation  with  Suxamethonium  was  not 
significantly different from that of Rocuronium, with a mean score of 2.85 and 3.0 respectively. 
The  response  to  intubation was  higher  in  the  Rocuronium  group  and  was  statistically 
significant (P = 0.001), from that of the Suxamethonium group. Rocuronium group showed a 
mean score of 2 ± 0.0 (slight diaphragmatic movement), and Suxamethonium group showed 
a mean score of 3 ± 0.0 (no response). The total intubation score with Suxamethonium was 
higher  than  that  of  Rocuronium and  was  statistically  significant  (P  =  0.001).  The overall 
intubating conditions were better with Suxamethonium with a mean total score of 9. The mean 
total  score  in  Rocuronium  group  was  7.85.  Though  Rocuronium  fell  back  against 
Suxamethonium with respect to the total scores, the mean score reflected good intubating 
conditions.
The  results  with  respect  to  intubating  conditions  in  the  present  study  go  well  in 
concurrence with the results of the study by Dr. Ajeet singh et al.
Moreover, the intubating conditions achieved at 60 secs, according to the present study, 
were also observed in the studies of Mirakhur R.K. et al 34, Clarke 11 , De Mey J.C., et al 13 , 
Lam AM., et al 27 , Mc Court et al 32. 
Rocuronium was used for emergency intubations in the present study, and the intubating 
conditions were good to excellent at 60 secs. This goes in concurrence with the methods and 
results obtained by Sparr 48 and Crul et al,12 
The mean rise in MAP and HR was higher within the groups (P = 0.001) during intubation, 
and  was  statistically  significant.  This  could  be  attributed  to  the  adrenergic  response  to 
laryngoscopy and  intubation, rather than to the effect of drugs. But the rise in MAP & HR 
between the groups (P = 0.3) showed no statistical significance. The hemodynamic conditions 
observed during intubation were comparable with the results of  Dr. Ajeet singh et al. This 
showed that the muscle relaxant administered during intubation did not alter or influence the 
hemodynamic state. Therefore Rocuronium, at the dose of 0.6 mg/kg (2 x ED95) did not show 
any  adverse  hemodynamic  response,  and  the  hemodynamic  profile  was  comparable  to 
Suxamethonium.
No sign of histamine release was noted in any of the patients, in this study. Two of the 
patients in Rocuronium group had hypertension and tachycardia, and 1 patient experienced 
pain during injection. No significant adverse effects were observed in Suxamethonium group. 
In the study by  Dr. Ajeet singh et al, complications such as laryngospasm, bradycardia, 
tachycardia and arrhythmias were noted in a significant number of patients in both the groups, 
but statistical analysis between the groups failed to show any significance.
 In the present study, statistical analysis with Chi-square test showed no significant 
difference in the adverse effects between both the groups (P = 0.19). Hence the results of the 
present study with respect to adverse effects are comparable with the study of  Dr. Ajeet 
singh et al.
SUMMARY
 Rocuronium 0.6mg/kg (2  x  ED  95)  produced acceptable intubating conditions (good or 
excellent) in 1 minute.
  Excellent intubating conditions were observed in Suxamethonium group at 1 minute.
 Rocuronium, at the dose of 0.6 mg/kg (2 x ED95) did not show any adverse hemodynamic 
response, and the hemodynamic profile was comparable to Suxamethonium.

CONCLUSION
Both  Rocuronium  and  Suxamethonium  produced  good  to  excellent  intubating 
conditions  for  rapid  sequence  intubation.  Rocuronium  in  the  dose  of  0.6  mg/kg,  had  a 
comparable  hemodynamic  profile  to  Suxamethonium,  and can  be  used as  the  next  best 
alternative to Suxamethonium as a part  of rapid sequence induction provided there is no 
anticipated difficulty in intubation. Rocuronium appears to be safe with less adverse effects 
and effective for rapid sequence intubation of selected patients in whom contraindications to 
Succinylcholine exist.
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A COMPARATIVE EVALUATION OF ROCURONIUM AND SUXAMETHONIUM 
FOLLOWING RAPID SEQUENCE INDUCTION IN EMERGENCY SURGERIES
PROFORMA
1. NAME: AGE/SEX: I.P.No:
2. WEIGHT :
3. DIAGNOSIS :
4. PROCEDURE PLANNED :
5. HISTORY IN BRIEF :
6. TIME SINCE LAST 
     MEAL/DRINK :
7. CO-EXISTING ILLNESS : DM/HT/PT/EPILEPSY/IHD
  HEPATIC/RENAL DISEASE
8. EXAMINATION : PULSE RATE - 
  RESP. RATE - 
  BP -
  CVS -
  RS -
  AIRWAY -
9. INVESTIGATIONS : Hb% -
  BLOOD SUGAR -
  BLOOD UREA -
  S. CREATININE -
  S.ELECTROLYTES - Na+
 - K+
10. DETAILS OF RSI :
a) Pre-oxygenation - 3 mins.
b) Pre-medication - Glycopyrrolate 0.2mg + Pentazocine 30mg            
   I.V.  5 mins. before induction
c) Induction - Thiopentone 5mg/kg
d) Cricoid pressure
e) Muscle relaxant - Suxamethonium – 1.5 mg/kg
- Rocuronium - 0.6 mg/kg
f) Intubation - at 60 secs.
Cooper’s Scoring System
SCORE JAW 
RELAXATION
VOCAL 
CORDS
RESPONSE TO INTUBATION
0 Poor(impossible) Closed Severe coughing or bucking
1 Minimal(difficult) Closed Mild coughing
2 Moderate(fair) Moving Slight diaphragmatic movement
3 Good(easy) Open None
g) Intubation score - 8 – 9 : excellent
- 6 – 7 : good
- 3 – 5 : fair
- 0 – 2 : poor
h) Laryngoscopy - Cormack & Lehane grade –
i) Confirmation of ETT placement- Inspection & auscultation
j) Cuff inflation and release of cricoid pressure
11. No. OF ATTEMPTS AT INTUBATION :
12. AIRWAY ADJUNCTS USED -    Combitube
- LMA
- Surgical airway
13. HEMODYNAMIC RESPONSE TO INTUBATION : 
baseline induction Intubation 1m 3m 5 m
HR
BP (MAP)
SpO2
14. ADVERSE EFFECTS:
 Arrhythmia
 Bradycardia
 Tachycardia
 Hypertension
 Hypotension
 Pain on injection
 Laryngospasm / Bronchospasm
 Prolonged apnoea
Anaphylactic / Anaphylactoid reactions
MASTER CHART
GROUP- I (ROCURONIUM 0.6 mg/kg)
Pt. 
no
Age/
Sex
map PR Intubation score Adverse 
effects
Base
line
Induction Intubation
     0 s
1 m 3m 5m Base
line
Induction Intubation
0 s
1m 3m 5m J V R T
18/M 81 76 88 89 99 99 96 107 113 94 92 88 3 3 2 8 Nil
20/M 88 77 95 97 98 96 68 82 94 96 88 76 3 3 2 8 Nil
25/M 97 83 107 102 95 96 77 89 101 103 96 89 3 2 2 7 Nil
40/M 130 118 136 133 134 130 82 97 121 115 112 96 3 3 2 8 HT, Tachy
19/M 87 78 92 90 88 86 102 111 122 126 114 98 3 2 2 7 Nil
42/F 86 80 89 90 89 88 84 88 102 104 101 92 3 3 2 8 Nil
22/M 89 79 95 93 90 91 109 93 135 133 131 126 3 3 2 8 Nil
32/M 122 110 132 133 130 127 112 116 132 136 126 114 3 3 2 8 HT, Tachy
37/F 95 86 104 102 100 97 89 99 4 110 102 92 3 3 2 8 Nil
10 29/F 89 77 95 94 93 90 92 109 111 99 96 97 3 3 2 8 Pain
11 25/M 94 86 99 100 98 97 88 94 102 99 94 89 3 3 2 8 Nil
12 35/M 110 99 121 118 116 115 92 99 108 105 99 89 3 2 2 7 Nil
13 20/M 80 72 94 92 90 87 68 77 86 82 80 74 3 3 2 8 Nil
14 52/F 111 98 122 120 119 115 94 107 119 121 109 108 3 3 2 8 Nil
15 29/M 104 90 118 120 116 115 78 87 94 96 91 88 3 3 2 8 Nil
16 42/M 100 88 111 110 108 106 80 92 98 99 91 87 3 3 2 8 Nil
17 28/F 97 83 108 110 109 105 84 99 104 105 98 94 3 3 2 8 Nil
18 32/F 83 69 98 100 99 96 98 114 124 122 111 105 3 3 2 8 Nil
19 24/M 87 71 101 98 96 92 87 98 106 111 107 99 3 3 2 8 Nil
20 31/M 104 95 128 120 115 110 74 84 97 99 91 86 3 3 2 8 Nil
MASTER CHART
GROUP- II (SUXAMETHONIUM 1.5 mg/kg)
Pt. Age/
Sex
MAP PR Intubation 
score
Base
line
Induction Intubation
0 s
1 m 3m 5m Base
line
Induction Intubation
0 s
1m 3m 5m J V R T
ADVERSE 
EFFECTS
28/M 97 85 103 102 100 98 84 96 112 108 105 99 3 3 3 9 Nil
22/M 99 91 107 106 103 100 78 88 106 105 100 84 3 3 3 9 Nil
35/M 96 87 105 105 102 100 77 86 99 95 88 89 3 3 3 9 Nil
40/F 70 77 93 92 90 86 68 75 88 85 80 76 3 3 3 9 Nil
29/M 88 81 93 91 90 87 70 76 84 87 81 83 3 3 3 9 Nil
32/F 101 90 110 109 105 101 85 99 108 105 101 97 3 3 3 9 Nil
22/F 91 81 96 95 93 90 88 92 99 98 94 96 3 3 3 9 Nil
33/M 109 97 119 116 115 110 92 100 109 105 101 99 3 3 3 9 Nil
37/M 103 96 106 104 103 101 82 93 98 101 97 95 3 3 3 9 Nil
10 29/F 78 74 95 96 94 90 99 118 124 120 117 112 3 3 3 9 Nil
11 25/M 82 78 93 93 92 88 66 78 85 82 80 76 3 3 3 9 Nil
12 35/M 103 91 109 108 107 105 72 85 97 95 90 85 3 3 3 9 Nil
13 20/M 85 79 96 95 94 90 76 82 96 92 89 88 3 3 3 9 Nil
14 52/F 100 91 103 102 101 100 90 105 115 110 109 105 3 3 3 9 Nil
15 29/F 89 81 94 93 92 90 83 96 105 101 98 95 3 3 3 9 Nil
16 42/M 99 89 106 105 104 101 78 85 95 92 89 85 3 3 3 9 Nil
17 28/F 111 93 117 115 113 110 104 114 128 132 126 118 3 3 3 9 Nil
18 32/F 93 82 105 104 103 100 96 106 129 125 118 109 3 3 3 9 Nil
19 24/M 86 78 101 100 99 95 75 80 95 92 88 82 3 3 3 9 Nil
20 31/M 84 78 102 100 98 93 80 86 99 95 91 86 3 3 3 9 Nil
